Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 12;1(4):291-298.
doi: 10.1002/mdc3.12057. eCollection 2014 Dec.

Treatment Options in Degenerative Cerebellar Ataxia: A Systematic Review

Affiliations
Review

Treatment Options in Degenerative Cerebellar Ataxia: A Systematic Review

Harini Sarva et al. Mov Disord Clin Pract. .

Abstract

The etiology of cerebellar ataxia (CA) is heterogeneous and includes easily identified and often reversible causes (i.e., drug toxicity and vitamin B12 deficiency) as well as irreversible degenerative conditions. It is the latter that poses a significant therapeutic challenge for practitioners treating this population of patients. To date, there are no U.S. Food and Drug Administration-approved medications for the treatment of CA. The literature, consisting mostly of case reports, case series, and small clinical trials, is sparse and scattered. These studies are difficult to translate clinically because they often describe diverse study populations with various identified and unidentified genetic etiologies. In addition, the reported treatment duration is often brief, and it is uncertain whether any of these options provide substantially lasting benefits. In this article, we review published reports and studies to aid the practitioner counseling patients with degenerative ataxias.

Keywords: cerebellar ataxia; physical therapy; treatment.

PubMed Disclaimer

References

    1. Fahn S, Jankovic J, Hallett M. Chapter 21: ataxia pathophysiology and clinical syndromes In: Principles and Practice of Movement Disorders, 2nd ed. Edinburg: Elsevier Saunders Ltd, Inc, BV; 2011:465–477.
    1. Nag N, Tarlac V, Storey E. Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. Cerebellum 2013;12:74–82. - PubMed
    1. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;6(suppl 4):S233–S241. - PubMed
    1. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double‐blind, placebo‐controlled pilot trial. Neurology 2010;74:839–845. - PubMed
    1. van de Warrenburg BPC, van Gaalen J, Boesch S, et al. EFNS/ENS consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol 2014;21:552–562. - PubMed

LinkOut - more resources